Literature DB >> 15205915

Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy.

István Takács, N Eros, I Bene, F Bozsó, L Tordai, Z Károlyi, G Radványi, A Matolcsy.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15205915     DOI： 10.1007/s00277-004-0897-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

1.  Intravascular large B cell lymphoma: proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition.

Authors:  Yasufumi Masaki; Lingli Dong; Akio Nakajima; Haruka Iwao; Miyuki Miki; Nozomu Kurose; Eriko Kinoshita; Takayuki Nojima; Toshioki Sawaki; Takafumi Kawanami; Masao Tanaka; Kumiko Shimoyama; Changi Kim; Masaaki Fukutoku; Hiroshi Kawabata; Toshihiro Fukushima; Yuko Hirose; Tomoo Takiguchi; Susumu Konda; Susumu Sugai; Hisanori Umehara
Journal:  Int J Hematol       Date:  2009-04-14       Impact factor: 2.490

2.  Chemotherapy-resistant intravascular lymphoma accompanied by ADAMTS13 inhibitor successfully treated with rituximab.

Authors:  Masatoshi Kanno; Shinobu Nakamura; Makoto Kawahara; Satoshi Ueno; Hirokazu Nakamine; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Int J Hematol       Date:  2008-08-19       Impact factor: 2.490

3.  A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.

Authors:  Jing Zeng; Ran Liu; Jinjing Wang; Yi Fang
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-14       Impact factor: 4.553

4.  [Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease].

Authors:  I Satzger; B Völker; D Kofahl-Krause; A Ganser; A Kapp; R Gutzmer
Journal:  Hautarzt       Date:  2009-02       Impact factor: 0.751
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.